Osimertinib works by selectively inhibiting both the EGFR tyrosine kinase domain and the T790M resistance mutation, which is often responsible for resistance to first and second-generation EGFR inhibitors. This dual-targeting ability allows osimertinib to be effective even in cases where earlier treatments have failed. By blocking these pathways, the drug induces cancer cell death and inhibits tumor growth.
